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Introduction: The World Health Organization classification of chronic myeloproliferative disease encompasses
eight entities of bone marrow neoplasms, among them Breakpoint cluster region-Abelson murine leukemia viral
oncogene homolog 1-positive chronic myeloid leukemia and polycythemia vera. Polycythemia vera requires, in
the majority of cases (95%), the negativity of Breakpoint cluster region-Abelson murine leukemia viral oncogene
homolog 1 rearrangement and the presence of the Janus kinase 2 mutation. We report a case of erythrocytosis as
the primary manifestation of a chronic myeloid leukemia, with the presence of the Philadelphia chromosome and
the Breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 fusion gene, and in the
absence of any Janus kinase 2 mutation.
Case presentation: A 68-year-old Caucasian woman, with a history of cigarette consumption and obstructive sleep
apnoea syndrome (undergoing continuous positive airway pressure treatment) had presented to our institution with
fatigue and a hemoglobin level of 18.6g/L, with slight leukocytosis at 16G/L, and no other anomalies on her complete
blood cell count. Examination of her arterial blood gases found only a slight hypoxemia; erythropoietin and ferritin
levels were very low and could not explain a secondary erythrocytosis.
Further analyses revealed the absence of any Janus kinase 2 mutation, thus excluding polycythemia vera. Taken
together with a high vitamin B12 level, we conducted a Breakpoint cluster region-Abelson murine leukemia viral
oncogene homolog 1 gene analysis and bone marrow cytogenetic analysis, both of which returned positive,
leading to the diagnosis of chronic myeloid leukemia.
Conclusions: To date, this case is the first description of a Breakpoint cluster region-Abelson murine leukemia viral
oncogene homolog 1-positive chronic myeloid leukemia, presenting with erythrocytosis as the initial manifestation,
and mimicking a Janus kinase 2 V617F-negative polycythemia vera. Her impressive response to imatinib therapy
underscores the importance of not missing this diagnosis.
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The World Health Organization 2008 classification of
myeloproliferative neoplasms (MPN) encompasses break-
point cluster region-Abelson murine leukemia viral oncogene
homolog 1 (BCR-ABL1)-positive chronic myeloid leukemia
(CML) and 7 Philadelphia-negative (Ph negative) MPN.
The BCR-ABL1 fusion gene is consistently found in
CML. Conversely, Janus kinase 2 (JAK2) mutations,* Correspondence: Mihaela.Precup@h-fr.ch
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unless otherwise stated.especially JAK2 V617F, are frequently encountered in Ph
negative MPN, particularly in polycythemia vera (>95%)
[1-3], primary myelofibrosis (50%) [3], and in essential
thrombocythemia (40 to 50%) [1]. Other gain of function
mutations in key proliferative genes such as MPL
W515K/L and, recently, in the calreticulin (CALR) gene,
have also been described in Ph negative MPN [4].
Although Ph negative MPN requires evidence of absence
of BCR-ABL1, CML may rarely harbor JAK2 mutations,
especially during evolution of the disease [4].
Neutrophilic leukocytosis is the initial major finding of
CML, which is defined by the World Health Organization. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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marrow stem cell, with the BCR-ABL1 fusion gene found
in all myeloid lineages, as well as in some lymphoid and
endothelial cells [2,3].
Erythrocytosis is usually the main feature of polycy-
themia vera and is considered, with one of the JAK2 muta-
tions, as a major criteria of this Ph negative MPN.
However, to our knowledge, it has never been reported so
far as a manifestation of CML. In our case report, we
describe a patient with isolated erythrocytosis as the sole
initial manifestation of BCR-ABL1-positive CML.
Case presentation
A 68-year-old Caucasian woman, with active tabagism
(40 pack-years), obstructive sleep apnoea syndrome under
continuous positive airway pressure (CPAP) via nasal
mask, and hypothyroidism secondary to a partial thyroid-
ectomy in 1979, was investigated by her practitioner for
fatigue in 2010. The current treatment at that time was
aspirin 100mg per day, levothyroxine 100μg per day, and
lorazepam 1mg per day. Her family history was negative
for any hematologic malignancy.
A hemoglobin (Hb) level of 177g/L and hematocrit
(HCT) level of 55% was found, with slight leukocytosis
at 12.3G/L, but there was no other abnormality found
on her blood smear, especially no left deviation or mye-
lemia. Therefore it was initially interpreted as secondary
erythrocytosis.
In 2012 a rise in her Hb level was noted and she was
seen at our institution for further investigation. Her test
results indicated a Hb level of 180g/L, a HCT level of
55%, a leukocytes count of 16G/L with normal differen-
tiation, a thrombocytes count of 294G/L, and a reticulo-
cytes count of 67G/L. Her arterial blood gas levels were:
partial pressure of oxygen in the arterial blood (PaO2) of
8.8kPa, partial pressure of carbon dioxide in the arterial
blood (PaCO2) of 4.7KPa, carboxyhemoglobin at 8.6%, a
pH of 7.42, and a base excess of −1.2mmol/L with
oxygen saturation at 95%. Her lactate dehydrogenase
value was 527U/L (normal value: <450U/L), with herFigure 1 Evolution of hemoglobin under imatinib mesylate therapy.liver test results showing normal function. Her erythro-
poietin and ferritin values were low at 2.3U/L (normal
value: 8 to 22U/L) and 16μg/L (normal value: 30 to
300μg/L), respectively. In this context, polycythemia vera
was suspected, but could not be confirmed by molecular
biology analysis as she was negative for the JAK2 V617F
mutation. Interestingly, her vitamin B12 level was very
high at 1,703pg/mL (normal value: 185 to 1,060pg/mL).
Her blood marrow biopsy revealed a slight hyper-
cellularity with discrete hyperplasia and slight atypia of
megakaryopoiesis, normal erythropoiesis with discrete
signs of dyserythropoiesis without hyperplasia, and normal
myelopoiesis. These abnormalities were aspecific and not
suggestive for a MPN. Based on hyperleukocytosis and a
high vitamin B12 level, we searched for the BCR-ABL1
fusion gene, which was surprisingly positive. Her bone
marrow conventional cytogenetic analysis revealed a
female karyotype with the presence of the Philadelphia
chromosome (t (9; 22) (q34; q11.2)) in 85% of metaphases.
An interphase fluorescence in situ hybridization (FISH)
analysis confirmed the BCR-ABL1 rearrangement in 88.5%
of interphases analyzed. In light of these results we
diagnosed a BCR-ABL1-positive CML, in chronic phase,
with a low risk Sokal score (0.62). Given the presence of
the Philadelphia chromosome (t (9; 22) (q34; q11.2)), we
did not search for exon 12 mutations.
We started a therapy of imatinib mesylate (daily dose of
400mg) on 13 April 2012, and she showed relatively good
tolerance. Under treatment, she obtained a complete
hematological response at three months, including rapid
disappearance of her erythrocytosis (see Figure 1),
normalization of absolute neutrophil count (see Figure 2)
with complete cytogenetic response and major molecular
responses being observed at six months (see Figure 3).
These responses were considered optimal according to
European LeukemiaNet criteria 2010 and 2013 [5].
Discussion
In 1951, William Dameshek, described the first concept
of myeloproliferative disorders defining five entities of
Figure 2 Evolution of absolute neutrophil count (ANC) under
imatinib mesylate therapy.
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thrombocythemia, primary myelofibrosis, and erythro-
leukemia [6]. More than five decades later, the revised
2008 World Health Organization classification [2] of
MPN encompasses eight entities, among them CML har-
boring the BCR-ABL1 translocation and polycythemia vera,
which both share a common stem cell-derived clonal heri-
tage, but different phenotypes (leukocytosis with myelemia
in CML and polycythemia in polycythemia vera). These
alterations result from an abnormal signal transduction,
secondary to mutations in genes encoding tyrosine kinase
proteins or related molecules (BCR-ABL1 fusion gene in
CML and JAK2 V617F mutation in polycythemia vera) [7].
In polycythemia vera, polycythemia is defined as an
increased mass of red blood cells and can be evaluated by
laboratory findings (Hb or HCT >99th percentile of
method-specific reference range for age, sex, and altitude of
residence) [2] or measurement of red cell volume by radio-
isotopic methods, allowing to differentiate between true
polycythemia, as in polycythemia vera, chronic obstructive
pulmonary disease, and paraneoplastic syndromes, andFigure 3 Molecular response under imatinib mesylate therapy. BCR/ABL, B
homolog 1.pseudoerythrocytosis found in a dehydration state, for
example.
Several diagnostic algorithms of newly diagnosed (ac-
quired) erythrocytosis investigation are based on erythro-
poietin levels to differentiate between primary (low
erythropoietin levels) with gene alterations and secondary
(high erythropoietin levels) erythrocytosis.
In our patient who smoked and was diagnosed with
sleep apnea, low erythropoietin levels prevented us
from trivializing her polycythemia and misdiagnosing a
hypoxemia-related erythrocytosis. Therefore, our report
here emphasizes the importance of erythropoietin level
measurement in all polyglobulic patients. We agree
with the algorithms of Tefferi et al. [3] and Spivak and
Silver [8] recommending erythropoietin level measure-
ment and searching for the JAK2 V617F mutation.
Other nonspecific markers are helpful in diagnosing
MPN, such as splenomegaly (absent here), high lactate
dehydrogenase, and high vitamin B12 levels, as in our
patient. Furthermore, low ferritin levels can contribute
to the diagnosis of primary polycythemia, reflecting high
iron consumption by increased erythropoiesis.
In the presence of primary polycythemia, further
investigations are indicated [3]: bone marrow analysis,
showing panmyelosis (hypercellularity with tri-lineage
growth) in polycythemia vera; bone marrow cytogenetic
analysis (presence of the Philadelphia chromosome in
CML); and molecular analysis (presence of the JAK2
V617F mutation in polycythemia vera and the BCR-
ABL1 fusion gene in CML). In fact, there have been
some rare case reports on patients harboring both the
BCR-ABL1 fusion gene, and the JAK2 V617F mutation.
However, the co-existence of both mutations appeared
during the evolution of the disease [9].
To the best of our knowledge, this is the first case report-
ing primary polycythemia associated with JAK2 V617F mu-
tation negativity, but with the presence of the BCR-ABL1
fusion gene, pathognomonic of a CML diagnosis. Wereakpoint cluster region-Abelson murine leukemia viral oncogene
Cornea et al. Journal of Medical Case Reports 2015, 9:30 Page 4 of 4
http://www.jmedicalcasereports.com/content/9/1/30therefore conclude based on the low erythropoietin level
and the BCR-ABL1 positivity, supporting the monoclonal-
ity of red stem cells, as well as the excellent evolution of
erythrocytosis under imatinib therapy, that polycythemia
without a high number of neutrophils may also be a feature
of CML.
Conclusions
To the best of our knowledge, this case is the first
description of a CML with erythrocytosis as the initial
manifestation, mimicking a JAK2 V617F-negative poly-
cythemia vera.
In such cases we propose therefore to always test not
only for the JAK2 V617F mutation or exon 12 muta-
tions, but also for the BCR-ABL1 fusion transcript and
to perform bone marrow cytogenetic analysis.
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